Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	$2.560	-0.78%	3,436
01/10/26	$2.580	+0.78%	16,774
30/09/26	$2.560	-1.54%	2,419
29/09/26	$2.600	-2.62%	6,671
28/09/26	$2.670	+1.52%	6,673

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.560USD

Average target price

12.00USD

Spread / Average Target

+368.75%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 00:00:00 03/10/2026 +04			5-day change	1st Jan Change
2.560 ^USD	-0.78%		-2.66%	+29.95%

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI

Market Cap	16.29M 14.47M 13.51M 12.31M 23.22M 1.57B 23.44M 163M 63.35M 801M 61.16M 59.83M 2.57B	P/E 2026 *	-1.53x	P/E 2027 *	-1.82x
Enterprise Value	16.29M 14.47M 13.51M 12.31M 23.22M 1.57B 23.44M 163M 63.35M 801M 61.16M 59.83M 2.57B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.09%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	KPRX	Delayed
CBOE	KPRX	Real-time

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI
08-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI
04-07	Kiora Pharmaceuticals Inc - Enters securities purchase agreement on April 3, 2026 - SEC filing	RE
04-06	Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-03	Kiora Pharmaceuticals, Inc. announced that it expects to receive $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-03	Kiora Pharmaceuticals, Inc. Announces Resignation of Eric J. Daniels, M.D., MBA as Chief Development Officer, Effective April 17, 2026	CI
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	CI
16/09/25	Kiora Pharmaceuticals files for mixed shelf offering of up to $100 million- SEC filing	RE

Kiora Pharmaceuticals, Inc. Stock

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Valuation: Kiora Pharmaceuticals, Inc.

Chart: Kiora Pharmaceuticals, Inc.

Latest news: Kiora Pharmaceuticals, Inc.

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

Press Releases: Kiora Pharmaceuticals, Inc.

News in other languages: Kiora Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Kiora Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09/02/24	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
06/11/23	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
14/08/23	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
12/05/23	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
09/02/23	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT

09-08	Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs	NE
08-19	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation	NE
08-07	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	NE
07-02	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium	NE
06-18	Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model	NE

1 day	-0.78%
1 week	-2.66%
1 month	+0.39%
3 months	-2.66%
6 months	+31.96%
Current year	+29.95%

1 week	2.55	2.67
1 month	2.47	2.85
Current year	1.77	2.91
1 year	1.76	2.95
3 years	1.76	8.98
5 years	1.76	788.4
10 years	1.76	21,060.02

Manager	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	46	26/07/2021
Melissa Tosca DFI	Director of Finance/CFO	46	01/07/2024
Stefan Sperl COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Praveen Tyle CHM	Chairman	66	21/09/2023
Aron Shapiro BRD	Director/Board Member	48	01/04/2021
Brian Strem BRD	Director/Board Member	46	26/07/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/09/26	Keith Lane	Free	General Counsel	55,000	1.2431%
01/07/26	Melissa Tosca	Tax	Chief Financial Officer	-911	0.0206%
01/07/26	Brian Strem	Tax	Chief Executive Officer	-1,869	0.0422%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIORA PHARMACEUTICALS, INC.	-0.78%	-2.66%	-6.91%	-50.96%	16.29M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.28%	-0.79%	+46.68%	+110.59%	39.05B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.25%

	2026 *	2027 *
Net sales	-	-
Net income	-9.48M -8.42M -7.86M -7.17M -13.52M -912M -13.64M -95.16M -36.87M -466M -35.6M -34.83M -1.5B	-16.84M -14.97M -13.97M -12.73M -24.01M -1.62B -24.23M -169M -65.5M -828M -63.24M -61.86M -2.66B
Net Debt	-	-